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Abstract
Purpose Vestibulotoxicity associated with cisplatin chemotherapy is known to exist, but the extent, severity, and impact 
is unclear from the literature. This study explored knowledge, experiences, and opinions of audiovestibular professionals 
about cisplatin vestibulotoxicity.
Methods An online survey was disseminated to clinicians working in the audiovestibular field.
Results Ninety-three respondents participated in the survey. Most professionals were aware of potential vestibulotoxicity 
associated with cisplatin chemotherapy. Thirty-three percent of the respondents reported that they had seen patients with 
cisplatin vestibulotoxicity. Forty percent of them were confident in making the diagnosis and in managing the patient in this 
situation. The prevalence and impact of vestibulotoxicity including practicality of the assessment should be considered when 
designing an effective vestibulotoxicity screening protocol.
Conclusion This study provides a better understanding of cisplatin vestibulotoxicity from the perspectives of audiovestibular 
clinicians, which will underpin appropriate detection and management of the condition.
Keywords Audiovestibular · Cisplatin · Vestibular · Vestibulotoxicity
Introduction
Cisplatin is a highly effective chemotherapeutic agent 
against a variety of life-threatening cancers, but its ototoxic 
effect is considerably problematic and limits usage and dos-
age [1]. Ototoxicity refers to drug-related damage affect-
ing the inner ear structures, which can be characterized by 
cochlear dysfunction or vestibular dysfunction or both [2]. 
A variable degree of irreversible hearing loss as a result 
of cisplatin treatment is well documented with a reported 
prevalence of 50–90%, depending on patient demographics, 
drug dosage, and differences in tools and grading system 
[3–5].
Given that the auditory and vestibular organs of the inner 
ear share vascular, neural, and fluid supplies [6, 7], an oto-
toxic drug may affect both compartments. The vestibular 
part of the inner ear plays a vital role in the complex and 
dynamic human balance system, together with interactions 
of visual, somatosensory, and central nervous systems [8]. 
Balance problems such as dizziness and unsteadiness can 
cause significant negative impact on quality of life [9] and 
substantial economic burden [10], especially in a vulnerable 
group of cancer survivors [11]. Whilst the existence of cis-
platin vestibulotoxicity is evident [12], the extent, severity, 
and impact are largely unclear from the literature, and seem 
to be under-reported and under-investigated.
Hearing surveillance to monitor cochleotoxic effects asso-
ciated with cisplatin chemotherapy is advised and imple-
mented in clinical practice [13, 14]. On the other hand, we 
are unaware of any established protocol for monitoring ves-
tibular function, and for the detection of balance dysfunction 
following exposure to potential ototoxic medications. This 
could be largely because the diagnostic criteria are unclear 
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and that the diagnostic equipment available is expensive. 
Handelsman et al. [15] proposed possible components of a 
vestibulotoxicity monitoring program comprising the head 
impulse test (HIT), dynamic visual acuity (DVA), postural 
control, head shake test, videonystagmography with caloric 
test, rotational test, video head impulse test (vHIT), vestibu-
lar evoked myogenic potentials (VEMPs), and posturogra-
phy test. However, further study is needed to determine an 
ideal protocol for assessing vestibular function during and 
after ototoxic medication.
Systemic administration of ototoxic medication, including 
cisplatin chemotherapy, should reasonably affect both ears in 
the same way. It is also sensible to assume that the clinical 
manifestations of patients with cisplatin vestibulotoxicity 
would be similar to those who have suffered bilateral vesti-
bulopathy from other causes, and the diagnostic principles of 
bilateral vestibulopathy could also be applied in this regard. 
Important diagnostic criteria of bilateral vestibulopathy by 
the Classification Committee of the Barany Society consist 
of chronic vestibular symptoms (unsteadiness plus either 
oscillopsia, or worsening of unsteadiness in darkness and/or 
on uneven ground), and bilaterally reduced vestibulo-ocular 
reflex (VOR) function documented by vHIT and/or caloric 
test and/or rotational test [16]. Nonetheless, there are also a 
wide range of related symptoms of drug-induced vestibulo-
toxicity evident in the published literature including dizzi-
ness, vertigo, nausea, and ataxia [17–19]. Valuable bedside 
examinations in the diagnosis of drug-induced vestibulotox-
icity, recommended in the literature, are the HIT, DVA, and 
clinical test of sensory interaction of balance (CTSIB) [20].
Previous work investigating clinician knowledge, attitude, 
or practice regarding ototoxicity is sparse, and none particu-
larly studied vestibulotoxicity. Steffens et al. [21] explored 
knowledge and attitude regarding cisplatin ototoxicity, and 
found that audiologists and oncologists had comprehensive 
knowledge and understanding of ototoxicity. The majority 
of respondents in that study thought that it was unlikely or 
slightly likely that balance disturbance would develop after 
cisplatin treatment. Studies exploring current practice sug-
gested that ototoxic monitoring programs do not seem to 
be consistently implemented and the protocols vary across 
clinical settings [21, 22]. Cancer patients are not routinely 
asked about ototoxic effects in an oncology consultation [21, 
23]. Typically, in the United Kingdom (UK), patients who 
complain of audiovestibular symptoms are referred either to 
Otolaryngology or Audiology Department. However, only 
10% of audiovestibular professionals in the UK reported that 
balance assessment was part of ototoxicity monitoring in 
their centres [22].
This international study explored the knowledge, experi-
ences, and opinions of audiovestibular healthcare profes-
sionals towards cisplatin vestibulotoxicity. The first objec-
tive addressed knowledge of drug-induced vestibulotoxicity, 
particularly on symptoms, clinical examination, and vestib-
ular function tests. The second objective determined their 
experiences and whether they had come across any patients 
with cisplatin vestibulotoxicity. Last, the third objective 
sought opinions on the possibility of cisplatin vestibulotox-
icity and the potential for a screening protocol.
Methods
Ethical approval was obtained from the East Midlands—
Nottingham Research Ethics Committee (18/EM/0369 date 
30/04/2019). The approval of the online survey study was a 
part of a larger clinical study conducting to explore preva-
lence and impacts of vestibulotoxicity associated with cis-
platin in adult survivors of cancer.
Study sample
The target study population was healthcare professionals 
working in the audiovestibular field namely Audiologists, 
Audiovestibular Physicians, Otolaryngologists, and Ves-
tibular Physiotherapists. To reach relevant participants, 
professional groups and social media channels were identi-
fied. An example of professional groups was the Balance 
Interest Group of the British Society of Audiology which 
is a multi-disciplinary team of professionals interested in 
balance disorders. The leaders of audiovestibular academic 
groups were contacted and asked to disseminate the invita-
tion email with the survey link to all members of their group. 
Audiology and Otolaryngologist Facebook groups included 
Audiology-Vestibular science forum, Audiovestibular Medi-
cine and Neuro-otology Interest Group, British Academy of 
Audiology, and American Academy of Audiology. The same 
information was posted on these social media groups by the 
member of the study team.
Questionnaire development
A questionnaire (Appendix 1) was developed to answer the 
specific research questions through discussion and consen-
sus within the study team. The questionnaire consisted of 
13 questions: demographic data (4), knowledge (5), experi-
ence (2), and opinions (2). All of the questions were closed 
except one question asking about the geographical loca-
tion. Response scales included single-choice option, mul-
tiple-choice options, and Likert scales. Questions assessing 
knowledge of clinicians regarding detection of drug-induced 
vestibululotoxicity were designed for the participants to 
choose more than one options if they know the answers, 
or they could choose to answer that they do not know. At 
the end of the questionnaire, there was an optional free 
text section asking for any comments and feedbacks which 
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guided qualitative data for analysis. The survey was created 
through the online platform developed by the University of 
Nottingham. All respondents provided online consent and 
their participation was voluntary. To minimize missing data, 
and hence bias, the survey was programmed to require an 
answer for all questions before being able to proceed to the 
next set of questions. Questions were also customized to 
each respondent by a skip logic such that Q 10.1–10.4 were 
asked only if the response to Q 10 was “yes”.
Piloting
As a pilot, five audiovestibular colleagues of the study team 
undertook the survey and feedback from these participants 
led to some minor changes. Some question clarifications 
were modified such as the phrase “bedside clinical exami-
nations” was used instead of “clinical tests” to state that the 
question referred to physical examination at the time and 
place of patient care but not the objective tests. The example 
of adding more option in certain questions was to put “par-
tial recovery” as a response option for the questions asking 
for outcome of the treated patient.
Data analysis
The categorical data for all closed questions were descrip-
tively analyzed, and data were expressed as percentages. 
Qualitative data from the final optional question were man-
aged by content analysis process [24]. The initial step was 
to read and re-read the free text provided to get a sense of 
the overall comments. Then, the texts were dividing up into 
smaller meaningful parts, condensed meaning units. Each 
condensed meaning unit was further coded and collated. 
Codes were then organized into a category that text’s con-
tent belongs together. Then both quantitative and qualitative 
information were utilized to complement each other.
Results
Characteristics of participants
There were 93 responses from audiovestibular medical pro-
fessionals. The characteristics of respondents are summa-
rized in Table 1. Sixty-three percent of participants were 
Audiologists, 20% were Otolaryngologists, and 9% were 
Audiovestibular physicians. Fifty-nine percent of them 
were in senior level, and 31% were in mid-career position. 
Almost 60% had been working in their job roles for more 
than 10 years. Eighty-three percent of them worked in the 
UK. The following results are presented in accordance with 
the three research objectives.
Knowledge
The most commonly selected answers of indicative symp-
toms of drug-induced vestibulotoxicity symptoms were 
unsteadiness (81.7%), trouble walking in the dark (78.5%), 
trouble walking on an uneven surface (74.2%), dizziness 
(69.9%), oscillopsia (63.4%), and vertigo (60.2%), nausea 
and vomiting (40.9%), visual-induced dizziness (39.8%), and 
ataxia (35.5%). Six percent of respondents reported other 
symptoms such as spatial disorientation, vague symptoms, 
features of endolymphatic hydrops, and head movement pro-
voked vestibular symptoms. The average number of symp-
toms selected per participant was 5.9 (SD = 2.5). Only 2% of 
respondents stated that they did not know the symptoms of 
drug-induced vestibulotoxicity. Figure 1 reveals the partici-
pants’ responses concerning indicative symptoms of drug-
induced vestibulotoxicity.
Participants’ answers considering physical examinations 
of clinical benefit in detecting drug-induced vestibulotoxic-
ity are displayed in Fig. 2. Physical examinations reported 
were the head impulse test (HIT) (81.7%), clinical test 
of sensory interaction of balance (CTSIB) (63.4%), and 
dynamic visual acuity (DVA) (52.7%), followed by Romb-
erg test, Unterberger test (stepping test), oculomotor test, and 
head shake test. Examples of other physical examinations 
were full neurological examination and positional tests. The 
average number of symptoms selected per participant was 
Table 1  Characteristics of participants
Characteristic Number (%)
Occupation
 Audiologists 59 (63%)
 Otolaryngologists 19 (20%)
 Audiovestibular physicians 8 (9%)
 Vestibular Physiotherapist 4 (4%)
 Others: Hearing Therapist 1, Advanced Practitioner 1, 
and Clinical Scientist 1
3 (3%)
Level of occupation
 Junior/trainee 9 (10%)
 Mid-career 29 (31%)
 Senior 55 (59%)
Year of working in the job role
 < 5 years 20 (22%)
 5–10 years 18 (19%)
 10–20 years 29 (31%)
 > 20 years 26 (28%)
Country of the service
 United Kingdom 78 (84%)
 Other countries: USA 2, Australia 2, India 2, Canada 
1, South Africa 1, Portugal 1, Libya 1, Colombia 1, 
Denmark 1, Saudi Arabia 1, Egypt 1, Nepal 1
15 (16%)
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3.7 (SD = 1.9). Six percent of participants reported they did 
not know what to answer.
Vestibular function tests of clinical value in detecting 
drug-induced vestibulotoxicity reported by participants were 
video head impulse test (vHIT) (81.7%), videonystagmog-
raphy with caloric test (79.6%), vestibular evoked myogenic 
potentials (VEMPs) (48.4%), rotational chair test (38.7%), 
and posturography (37.6%). Three percent indicated that no 
vestibular function test was needed and clinical testing was 
sufficient for the diagnosis of drug-induced vestibulotoxic-
ity. An example of another test was the suppression head 
impulse test (SHIMP), a new paradigm of vHIT [25]. Nearly 
10% of participants indicated that they did not know what to 
answer. Figure 3 shows the participants’ responses reflecting 
vestibular function tests of clinical value.
Regarding confidence levels of participants in diagnosis 
and management of drug-induced vestibulotoxicity, approxi-
mately 40% of respondents reported that they were confi-
dent. Another 30% reported that they were neither confident 
nor unconfident. Almost 30% of them reported they were 
either somewhat unconfident or very unconfident. There 
was a high association between the degree of confidence in 
diagnosis and in management, demonstrated by Spearman’s 
rank correlation value of 0.79.
Experiences
Thirty-one (33%) respondents reported consultations with 
patients with cisplatin vestibulotoxicity. Thirty-eight per-
cent reported that they had never seen any patients with this 
condition, and 29% of participants were not sure about this.
Participants’ experiences of the condition were associated 
with the degree of confidence in diagnosis and management. 
Seventy-seven percent of respondents who had seen patients 
with cisplatin vestibulotoxicity felt confident in making 
diagnosis of drug-induced vestibulotoxicity, compared to 
31% and 22% in the group with no experience and the unsure 
group, respectively. Furthermore, 37% of participants in the 
no experience and unsure groups were unconfident in mak-
ing the diagnosis. Sixty-five percent of respondents who 
had seen patients were confident in the management of the 
condition, whilst there were 29% in no experience group and 
22% in the unsure group. Thirty-four percent of participants 
in the no experience and unsure groups felt unconfident in 
the management.
Participants who reported that they had seen patients 
with the condition were further asked about their experi-
ences. Clinical symptoms and vestibular function tests were 
parts of diagnostic criteria, described by more than 80% of 
respondents. Physical examinations and hearing test were 
also utilized by approximately 60%. Others were based on 
neurological examinations, or the diagnosis made by other 
clinicians. A report of diagnostic components for patients 
with cisplatin vestibulotoxicity is showed in Fig. 4.
Clinical experience of clinicians to cisplatin vestibu-
lotoxicity is summarized in Table 2. Nineteen of the 31 
(61.3%) participants who had seen patients with cisplatin 
vestibulotoxicity reported that they had seen 2–5 patients 
with the condition. Eight participants (25.8%) indicated 
that they had seen more than five patients, whilst four 
participants (12.9%) reported that they had seen one 
patient with the condition. Twenty-nine participants 
(93.5%) treated the patients by vestibular rehabilitation. 
Some provided counselling (51.6%), and some referred 
patients to other specialties for management (16.1%). 
Two clinicians (6.5%) stated that discussions were held 
with oncology colleagues to consider adjusting the cis-
platin dose or seeking alternative medication. Only one 
participant (3.2%) treated the patient with medication. 
Partial recovery was the most common outcome of the 
management that was reported by 23 participants (74.2%), 
Fig. 1  Indicative symptoms of 
drug-induced vestibulotoxicity
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followed by persistent symptoms reported by four partici-
pants (12.9%). Only one clinician (3.2%) stated that his/
her patient(s) had complete recovery. Three participants 
(9.7%) were unsure about the outcomes as the patients 
were followed up outside their services.
Fifty-five (59.1%) participants had seen and managed 
patients with drug-induced vestibulotoxicity caused by 
other medications, which were aminoglycoside antibiotics 
(94.5%), loop diuretics (12.7%), and nonsteroidal anti-
inflammatory drugs (7.3%).
Opinions on the possibility of cisplatin 
vestibulotoxicity and a screening protocol
Thirty-two percent of respondents thought that cisplatin 
often causes vestibulotoxicity, and 52% of them thought 
that cisplatin vestibulotoxicity is possible. Three percent 
thought that cisplatin always causes vestibulotoxicity, and 
4% thought the effect was unlikely. Nine percent answered 
that they do not know, and none of them answered that cis-
platin cannot cause vestibulotoxicity.
Figure 5 displays respondents’ opinions of the impor-
tance of each factor on the desirability of a vestibulotoxicity 
screening protocol. More than 80% of participants acknowl-
edged that the impact of vestibulotoxicity, awareness of cli-
nicians, and practicality of the vestibular screening protocol 
were extremely or very important. The prevalence of ves-
tibulotoxicity and duration of the screening protocol were 
thought to be extremely or very important by 70% and 60% 
of participants, correspondingly.
General comments
Twenty-five statements were provided in the free text option. 
These were coded and categorized into four themes: knowl-
edge (four comments), experience (seven comments), opin-
ions on screening protocol (ten comments), and current 
practice (four comments). Explanations and examples are 
given below.
Knowledge
Some comments emphasized the importance of understand-
ing the effect of ototoxic medication on cochlear and ves-
tibular functions, which will further lead to increased aware-
ness of ototoxic drug and its impact. An example of these 
Fig. 2  Useful physical examina-
tions in detecting drug-induced 
vestibulotoxicity
Fig. 3  Useful vestibular func-
tion tests in detecting drug-
induced vestibulotoxicity
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statements was “Clinicians should notice the ototoxic agents 
and the degree of disability they cause”. One respondent 
stated that “I now feel totally incompetent. So now I shall 
read up and learn”, suggesting the self-perceived low con-
fidence in dealing with the patient whilst willing to learn 
more. Not only sufficient knowledge on the topic but also 
practical clinical skill seems to be crucial in clinical practice, 
for example, “Interpreting head impulse testing takes some 
experience and expertise”.
Experience
The participants reported varying degree of exposure to ves-
tibulotoxicity. One respondent stated that “Cisplatin seems 
to be more cochleotoxic than vestibulotoxic”, this was also 
confirmed further by another respondent specified that “I 
always inform about the possibility but I only see very few 
cases”. In addition, it is difficult to disentangle vestibulotoxic 
effect between general deconditioning of cancer patients 
receiving cisplatin. Vestibular rehabilitation seems to be 
important in relieving patient symptoms and better qual-
ity of life. One respondent commented that “If caught early 
then rehabilitation can be put in place sooner. The sooner 
someone is seen for rehabilitation the better especially when 
looking at the anxiety that imbalance can cause”.
Opinions on a screening protocol
Clinical judgement appears to be influential in opinions on a 
screening protocol, for example, one participant commented 
that “I think screening with DVA would be an appropriate 
bedside test, and vHIT for the lab test. Rotatory chair is more 
sensitive, but unfit as a screening tool”. Clinical experience 
also plays a significant role. One example of these state-
ments was “In our experience, benign paroxysmal positional 
vertigo could occur secondary to damage caused by vesti-
bulotoxic medication and should be looked for in screening 
protocol”.
Current practice
Current practice regarding vestibular screening program has 
been reported to be varying from no testing at all to full 
examination in all patients receiving cisplatin. One respond-
ent emphasized that “We perform screening pure tone audio-
gram before commencing ototoxic medications for patients 
receiving treatment for testicular cancer but not vestibular 
screening”, indicating the implementation of only hearing 
surveillance protocol. Whilst another participant mentioned 
that “In my hospital, vestibular examination is integral to 
manage patients receiving cisplatin and other compounds”. 
Fig. 4  Criteria for diagnosis 
patient with cisplatin vestibulo-
toxicity
Fig. 5  Opinions on factors 
contributing to the desirability 
of a vestibulotoxicity screening 
protocol
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One respondent also stated that “I screen using the rotating 
chair in a paediatric service”.
Discussion
This survey received a response from relevant healthcare 
professionals including 60% being ‘senior’ clinicians. Some 
general comments from the respondents could confirm and 
explain the quantitative results of the survey. The discussion 
gathers the insights together in summary form and makes 
some comments on the findings.
Diagnosis of the cisplatin vestibulotoxicity
The common selected answers of indicative symptoms, 
bedside examinations, and vestibular function test of drug-
induced vestibulotoxicity were most closely associated with 
the proposed diagnostic criteria of vestibulotoxicity and 
bilateral vestibulopathy [15, 16, 20]. It is also recognized 
by healthcare professionals that there were a wide range of 
possible suggestive symptoms of drug-induced vestibulo-
toxicity, which is congruent with the literature [17–19]. The 
majority of respondents agreed that some kind of quantita-
tive vestibular function test was needed, and bedside testing 
alone was not sufficient to make the diagnosis of cisplatin 
vestibulotoxicity.
Most clinicians stated the utility and usefulness of vHIT 
in diagnosing drug-induced vestibulotoxicity, possibly 
because its practicality, portability, and high specificity in 
the diagnosis of vestibular disorders [26]. So far, only one 
study evaluated VOR function using vHIT and revealed 3 
out of 12 (25%) paediatric cancer patients had decreased 
VOR gain [27]. Interestingly, rotational chair testing, which 
is considered to be the gold standard in diagnosing bilateral 
vestibular loss [28, 29], was reported to be useful in the 
diagnosis by a substantially fewer number of respondents 
compared to that of the vHIT and caloric test. A qualita-
tive statement mentioned that the rotatory chair is unfit as 
a screening tool though its high sensitivity could be one of 
the explanations of this finding. Nearly half of participants 
reported the usefulness of VEMPs in making the diagnosis. 
VEMPs is one possible component in a proposed vestibu-
lotoxicity monitoring program [15], but it is not included in 
the diagnostic criteria of bilateral vestibulopathy [18]. This 
could be because the degree of otolith dysfunction appears 
to be less than that of canal dysfunction in bilateral vesti-
bulopathy [16]. None of the studies evaluated otolith func-
tion by VEMP in cancer populations who received cisplatin 
chemotherapy [12]; therefore, its utility has not yet been 
fully investigated.
Clinical experience
It is well-known that aminoglycoside antibiotics and cis-
platin chemotherapy are the most common medications 
causing ototoxic effects [7]. Thirty-three percent of the 
respondents reported that they had come across patients with 
cisplatin vestibulotoxicity, whilst 56% had seen patients with 
vestibulotoxicity caused by aminoglycoside antibiotics. The 
results suggest that vestibulotoxicity associated with cispl-
atin chemotherapy may not be as uncommon as it seemed in 
the literature. In this study, most of the respondents thought 
that cisplatin often or possibly causes vestibulotoxicity. On 
the other hand, in another study, the likelihood of develop-
ing balance disturbances in patients receiving cisplatin was 
reported to be “unlikely” to “slightly likely” by the majority 
of audiologists and oncologists [21]. This could be because 
the opinions were gathered from different clinical settings.
Confidence level in diagnosis and management of the 
condition was corresponding to the clinical experience 
whether they had seen any patient or not. Remarkably, one-
third of them reported being unsure whether they have come 
across this condition or not. The reasons behind this were not 
available from the survey results and should be further inves-
tigated. These findings show uncertainty in making the diag-
nosis and management of drug-induced vestibulotoxicity, 
indicating that there is substantial room for improvement.
The outcomes of patients with cisplatin vestibulotoxicity 
were mostly described to be poor, even after vestibular reha-
bilitation, which corresponds with the existing literature that 
the prognosis of bilateral vestibular hypofunction is poor and 
most patients do not improve with time [30]. Consequently, 
early identification of a patient at risk or prompt diagnosis 
could help prevent permanent debilitating balance problems.
Table 2  Clinician experience with cisplatin vestibulotoxicity
Clinician experience Number (%)
Number of patients seen
 1 4 (12.9%)
 2–5 19 (61.3%)
 > 5 8 (25.8%)
Management
 Vestibular rehabilitation 29 (93.5%)
 Counselling 16 (51.6%)
 Referral to other specialties for management 5 (16.1%)
 Medication 1 (3.2%)
 Other:  Decisions taken at oncology department 2 (6.5%)
Outcome
 Complete recovery 1 (3.2%)
 Partial recovery 23 (74.2%)
 Persistent symptoms 4 (12.9%)
 Other: Unknown 3 (9.7%)
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Suggestions for clinical practice
We suggest some practical strategies to improve the qual-
ity of management pathway of cisplatin and other drug-
induced vestibulotoxicity. First, more training at individual 
level should be encouraged. Although a lot of respondents 
had never dealt with any patients hence did not have direct 
experience, a sufficient level of knowledge to detect the con-
dition with a high index of suspicion should be stimulated. 
The provision of lectures, workshops, and case discussions 
could be beneficial in this regard. Second, clinical consulta-
tion with more experienced specialists should be supported 
in each clinical practice. Direct clinical experience had 
significant influence on confidence level in diagnosis and 
management; hence, educational role of more experienced 
professionals should be promoted.
Currently, vestibulotoxicity monitoring program is not 
regularly undertaken in clinical settings [22]. A flexible and 
compassionate approach is necessary especially when quan-
titative vestibular function test is not available or transporta-
tion of patients to laboratory setting is not possible. Bedside 
testing is certainly preferable to no testing at all [31].
Although most audiovestibular healthcare professionals 
in this study were aware of potential cisplatin vestibulotoxic-
ity, it is the Oncologists who will be the clinicians that will 
come across the affected patient initially. Therefore, working 
in collaboration with Oncologists is crucial in this situa-
tion. The present study did not determine levels of awareness 
amongst Oncology clinicians. A recent study emphasized 
the role of the Audiologist as a clinical team member in the 
care plan of patients receiving ototoxic medication [32]. The 
management of ototoxicity ideally should be based on a team 
approach involving both Audiologists and Oncologists [21].
Limitations
There are some limitations to be taken into account when 
interpreting the results of this study. First, participants 
were self-enrolled into the study which could lead to selec-
tion bias. For example, it can be assumed that clinicians 
were more likely to have undertaken the survey if they had 
knowledge of cisplatin vestibulotoxicity or were interested 
in the topic. It is also possible that clinicians did not want to 
admit that they did not previously know about cisplatin ves-
tibulotoxicity and therefore might exaggerate their current 
knowledge and experience in the subject. This could occur 
as many items in the questionnaire had potentially leading 
questions. However, we believe that the results are reason-
ably illustrative view of audiovestibular professionals since 
we approached potential participants via relevant academic 
and social media groups who seem to be working actively 
in clinical settings. Second, convenience sampling limits 
the interpretation of results to the specific context including 
population group, clinical setting, and country of the service. 
For example, most of respondents in this study are working 
in the UK so the findings might represent UK perspectives 
and contexts. The findings still provide a snapshot of the 
current situation and practice.
Conclusion
Most of the audiovestibular professionals in this survey are 
aware of potential vestibulotoxicity associated with cisplatin 
chemotherapy, and some had seen patients with the condi-
tion. However, there is substantial room for improvement in 
knowledge, diagnostic protocol, and management. Relevant 
healthcare professionals should refresh their knowledge and 
actively promote their roles in the diagnosis and manage-
ment of vestibulotoxicity. In summary, this study provides a 
better understanding of the perspectives of audiovestibular 
clinicians of cisplatin vestibulotoxicity, which will underpin 
appropriate detection and management of this debilitating 
condition.
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Appendix 1: Questionnaire
1. What is your occupation?
Audiologist
Audiovestibular physician
ENT doctor
Vestibular physiotherapist
Other (please specify)
2. What level of your occupation would you say you 
were?
Student
Junior/traine
Mid-career
Senior
3. How long have you been working in your job role?
< 5 years
5–10 years
10–20 years
> 20 years
4. Which country is the location of your service?
5. What do you think are the indicative symptoms of 
patients who have drug-induced vestibulotoxicity?—You 
may choose more than one option.
Vertigo
Dizziness
Unsteadiness
Ataxia
Oscillopsia
Trouble walking in the dark
Trouble walking on an uneven surface
Visual-induced dizziness
Nausea, vomiting
Don’t know
Other (please specify)
6. What bedside clinical examinations do you think are 
useful to detect patients who may have drug-induced ves-
tibulotoxicity?—You may choose more than one option.
Oculomotor test such as smooth pursuit
Head impulse test
Head shake test
Dynamic visual acuity (DVA)
Romberg test
Clinical test of sensory interaction of balance (CTSIB) 
or foam Romberg test
Unterberger test (stepping test)
Don’t know
Other (please specify)
7. What vestibular function tests do you think are useful 
to detect patients who may have drug-induced vestibulo-
toxicity?—You may choose more than one option.
No vestibular function test is needed/clinical testing is 
adequate
Videonystagmography (VNG) with caloric test
Rotational chair test
Video head impulse test (vHIT)
Vestibular evoked myogenic potentials (VEMPs)
Posturography
Don’t know
Other (please specify)
8. How confident are you in the diagnosis of drug-
induced vestibulotoxicity?
Confident
Neither confident nor unconfident
Unconfident
9. How confident are you in the management of drug-
induced vestibulotoxicity?
Confident
Neither confident nor unconfident
Unconfident
10. Have you ever come across patient(s) who has ves-
tibulotoxicity associated with cisplatin?
Yes. If Yes, then answer Q10.1–10.4
No. If No, then answer Q11
Not sure. If Not sure, then answer Q11
10.1 How did you diagnose patient with this condi-
tion?—You may choose more than one option.
Clinical symptoms
Physical examinations
Vestibular function test
Hearing test
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Other (please specify)
10.2 How many patients with presumed cisplatin vesti-
bulotoxicity have you seen in total?
1
2–5
 > 5
10.3 How did you treat them?—You may choose more 
than one option.
Counselling
Referred to other specialty for proper diagnosis
Referred to other specialty for proper management
Medication
Vestibular rehabilitation
I did not know how to treat them
Other (please specify)
10.4 What was the outcome of (most of) the treated 
patient with cisplatin vestibulotoxicity?
Complete recovery
Partial recovery
Persistent symptoms
Other (please specify)
11. Have you ever seen and managed patients with other 
drug-induced causes of vestibulotoxicity? 
Yes. If Yes, what was the drug?—You may choose more 
than one option
Aminoglycoside antibiotics
Loop diuretics
NSAIDs
Other (please specify)
No
Not sure
12. To what extent do you think that cisplatin can cause 
vestibulotoxicity in adults?
Yes, always
Yes, often
Yes, possible
Yes, but unlikely
No
Don’t know
13. How important do you think the following factors 
are in contributing to your perspective on the desirability 
of a vestibulotoxicity screening protocol? (Please select 
one answer in each row.)
Extremely 
important
Very 
important
Somewhat 
important
Not so 
impor-
tant
Not at all 
important
Prevalence 
of vesti-
bulotox-
icity
Impact of 
vestibu-
lotoxic-
ity
Awareness 
of clini-
cians
Practical-
ity of the 
ves-
tibular 
screen-
ing test
Duration 
of the 
ves-
tibular 
screen-
ing 
assess-
ment
14. General comments.
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